Cargando…

Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes

The effects of chronic coffee exposure in models of type 2 diabetes mellitus (T2D) is scarcely studied, and the efficacy of the main coffee species has never been compared. We tested the hypothesis that long-term consumption of arabica and robusta coffee may differentially delay and affect T2D devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokouh, Pedram, Jeppesen, Per B, Christiansen, Christine B, Mellbye, Fredrik B, Hermansen, Kjeld, Gregersen, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770458/
https://www.ncbi.nlm.nih.gov/pubmed/31484373
http://dx.doi.org/10.3390/nu11092074
_version_ 1783455477722513408
author Shokouh, Pedram
Jeppesen, Per B
Christiansen, Christine B
Mellbye, Fredrik B
Hermansen, Kjeld
Gregersen, Søren
author_facet Shokouh, Pedram
Jeppesen, Per B
Christiansen, Christine B
Mellbye, Fredrik B
Hermansen, Kjeld
Gregersen, Søren
author_sort Shokouh, Pedram
collection PubMed
description The effects of chronic coffee exposure in models of type 2 diabetes mellitus (T2D) is scarcely studied, and the efficacy of the main coffee species has never been compared. We tested the hypothesis that long-term consumption of arabica and robusta coffee may differentially delay and affect T2D development in Zucker diabetic fatty rats. Three study groups received either chow mixed with arabica or robusta instant coffee (1.8% w/w) or unsupplemented chow food for 10 weeks. Both coffee species reduced liver triglyceride content and area under the curve of fasting and postprandial insulin. At study end, plasma adiponectin, total cholesterol and high density lipoprotein levels were higher in the robust group compared with both arabica and control groups. The liver gene expression of Glucose-6-phosphatase, catalytic subunit (G6pc) and Mechanistic target of rapamycin (mTOR) in robusta and Cpt1a in both coffee groups was downregulated. In conclusion, long-term consumption of both coffee species reduced weight gain and liver steatosis and improved insulin sensitivity in a rat model of T2D. Robusta coffee was seemingly superior to arabica coffee with respect to effects on lipid profile, adiponectin level and hepatic gene expression.
format Online
Article
Text
id pubmed-6770458
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67704582019-10-30 Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes Shokouh, Pedram Jeppesen, Per B Christiansen, Christine B Mellbye, Fredrik B Hermansen, Kjeld Gregersen, Søren Nutrients Article The effects of chronic coffee exposure in models of type 2 diabetes mellitus (T2D) is scarcely studied, and the efficacy of the main coffee species has never been compared. We tested the hypothesis that long-term consumption of arabica and robusta coffee may differentially delay and affect T2D development in Zucker diabetic fatty rats. Three study groups received either chow mixed with arabica or robusta instant coffee (1.8% w/w) or unsupplemented chow food for 10 weeks. Both coffee species reduced liver triglyceride content and area under the curve of fasting and postprandial insulin. At study end, plasma adiponectin, total cholesterol and high density lipoprotein levels were higher in the robust group compared with both arabica and control groups. The liver gene expression of Glucose-6-phosphatase, catalytic subunit (G6pc) and Mechanistic target of rapamycin (mTOR) in robusta and Cpt1a in both coffee groups was downregulated. In conclusion, long-term consumption of both coffee species reduced weight gain and liver steatosis and improved insulin sensitivity in a rat model of T2D. Robusta coffee was seemingly superior to arabica coffee with respect to effects on lipid profile, adiponectin level and hepatic gene expression. MDPI 2019-09-03 /pmc/articles/PMC6770458/ /pubmed/31484373 http://dx.doi.org/10.3390/nu11092074 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shokouh, Pedram
Jeppesen, Per B
Christiansen, Christine B
Mellbye, Fredrik B
Hermansen, Kjeld
Gregersen, Søren
Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title_full Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title_fullStr Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title_full_unstemmed Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title_short Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes
title_sort efficacy of arabica versus robusta coffee in improving weight, insulin resistance, and liver steatosis in a rat model of type-2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770458/
https://www.ncbi.nlm.nih.gov/pubmed/31484373
http://dx.doi.org/10.3390/nu11092074
work_keys_str_mv AT shokouhpedram efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes
AT jeppesenperb efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes
AT christiansenchristineb efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes
AT mellbyefredrikb efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes
AT hermansenkjeld efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes
AT gregersensøren efficacyofarabicaversusrobustacoffeeinimprovingweightinsulinresistanceandliversteatosisinaratmodeloftype2diabetes